Author: Mokhtar

New Shotel™ medical ankle arthrodesis device significantly improves patient quality of life

Reduces time to weight bearing to two weeks from the current six to eight weeks

ATLANTA , Nov. 28, 2023 /PRNewswire/ — Shotel Medical today announced its Shotel™ Ankle Arthrodesis Nail System, which utilizes a novel device design for the treatment of end-stage ankle arthritis. It was used for the first time in Florida last month during a procedure in Delray Beach. Two weeks postoperatively, the patient was weight-bearing with the use of a CAM walking shoe, a significant improvement over the six- to eight-week time to weight-bearing offered by traditional ankle arthrodesis systems.

The patented Shotel Nail System, manufactured and distributed by BioPro Implants, differs from traditional ankle arthrodesis devices because its unique curved design allows for a minimally invasive approach with very small incisions. It is designed to achieve fusion at the tibiotalar joint while allowing unrestricted motion at all other joints. This benefits the patient with faster healing, faster recovery and faster loading. End-stage ankle arthritis is becoming increasingly common and can lead to significant physical disability. There are an estimated 50,000 new cases of ankle arthritis in the US each year¹

“We designed our ankle fusion nail system so that patients have smaller incisions, allowing them to heal faster and function much earlier, giving them a better quality of life. The improvement in time to weight bearing for the patient is meaningful,” said Christopher Weathers, Chief Commercial Officer. “We are pleased to see our Shotel nailing system gaining traction among surgeons across the country. So far, 24 operations have been performed with it.”

Kevin Palmer, DPM, dual board certified podiatrist from Boca Raton and Delray Beach, FL, who performed the procedure, said, “The patient presented with progressively worsening ankle disease and pre-existing structurally compromised hardware. The new design of the Shotel Nail System gave me confidence that it would be stable and would hold up over the long term. During the procedure, after I removed the patient’s current hardware, the Shotel Nail System was inserted smoothly, with a smaller incision and a much less invasive approach than traditional ankle fusion systems. I also like that it provides multiple layers of compression, which is needed at the fusion site to speed healing.

“I cannot emphasize enough how important it is that the patient started walking with a CAM walking shoe within two weeks,” added Dr. Palmer added. “This will be a game changer – and life changing – for many patients in the future.”

For more information about the Shotel™ Ankle Arthrodesis Nailing System or for surgical training, visit www.shotelmedical.com.

About Shotel Medical
Shotel Medical is the developer of the Shotel™ Ankle Arthrodesis Nail System, an entirely new device that has the potential to transform patient care and have a significant impact on the healthcare landscape. Developed in collaboration with a team of biomechanical engineers, orthopedic surgeons and industry thought leaders, the device addresses the needs of patients with end-stage ankle arthritis. The unique design allows patients to heal faster, function sooner and improve quality of life compared to current treatment options. Founded in 2017, the company has offices in New Orleans and Atlanta.

About BioPro
For more than three decades, BioPro has been at the forefront of orthopedic innovation, focused on improving the lives of patients suffering from orthopedic conditions. The company is committed to developing advanced implants and surgical devices that reduce pain and restore function, providing patients and surgeons with a diverse portfolio of established solutions and emerging technology. For more information, visit https://bioproimplants.com/.

Media contact:
Barbara Bikkel
305-215-2121
369140@email4pr.com

___________________________________
¹ Smyth, Niall A. MD; Dawkins, Brody J.BA; Goldstein, Joshua P.B.S.; Kaplan, Jonathan R. MD; Schon, Lew C. MD; Aiyer, Amiethab A. MD. Consumer prices for surgical treatment of ankle arthritis: limited availability and high variability. JAAOS: Global Research and Reviews 3(7):p e011, July 2019. | DOI: 10.5435/JAAOSGlobal-D-19-00011

SOURCE Shotel Medical

Source link

November 28, 2023
DISC Surgery Center in Newport Beach is now enrolling patients in a clinical trial of artificial disc replacement

Drs. Ali H. Mesiwala and Grant D. Shifflett participate in the pivotal two-level study of the safety and effectiveness of the Orthofix M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion.

NEWPORT BEACH, Calif., Nov. 28, 2023 /PRNewswire/ – DISC Surgery Center of Newport Beach (“DISC”), committed to supporting research vital to the field of spine care, has announced its participation in a clinical trial to artificial disc replacement and is now enrolling qualified patients. Candidates may include patients between the ages of 18 and 75 who have been told they need cervical (neck) surgery at two consecutive levels (among other requirements).

Drs. Ali H. Mesiwala and Grant D. Shifflett – both board-certified, fellowship-trained spine surgeons at DISC – join other experts at approximately 30 clinical sites participating in this study across the country. The primary objective of the study is to evaluate the safety and effectiveness of the Orthofix M6-C™ artificial cervical disc (already FDA-approved for single-level surgery) in patients with contiguous symptomatic bilevel cervical radiculopathy, with or without umbilical cord compression. The results will then be compared with those in patients undergoing anterior cervical discectomy and fusion (ACDF).

Artificial disc replacement surgery is very similar to ACDF surgery. Both procedures remove the damaged disk. However, when the damaged disc is removed to replace the disc, the space between the vertebrae is filled with a specialized implant called an artificial disc, instead of a bone graft. The artificial disc is designed to restore the distance between the vertebrae while still allowing some movement.

With its track record as a national leader in outpatient spine and its team’s extensive experience performing advanced motion maintenance techniques, DISC is ideally positioned to participate in such research.

“The DISC Surgery Center in Newport Beach has placed more than 3,000 cervical discs since 2018 and we are well versed in the motion-preserving qualities of the surgery,” said Dr. Mesiwala. “I think it is important to stay actively involved in research to improve patient care, so I wanted to be part of a study that will improve our learnings and discoveries.”

Dr. Shifflett added, “As pioneers in minimally invasive spine surgery and techniques, we always welcome the opportunity to advance the field while informing the treatment options available to patients.”

Patients who would like to know if they are eligible for this study can visit https://www.discmdgroup.com/adr-clinical-study/.

About DISC Surgery Center in Newport Beach
DISC Surgery Center in Newport Beach is a purpose-built outpatient clinic focused on providing patients with the safest, most advanced minimally invasive spine surgery, orthopedic sports medicine, total joint replacement and pain management. DISC is a subsidiary of TriasMD, a portfolio company of Chicago Pacific Founders, and also an official partner of Red Bull Athlete Performance Center. For more information, call 949-988-7800, visit www.discmdgroup.com or follow @DISCMD on Instagram.

Media contact:
Kristien Brada-Thompson
760-274-6393
369218@email4pr.com

SOURCE DISC Sports and Spine Center

Source link

November 28, 2023
Non-arthritic hip pain with Keelan Enseki

Hip pain is common in athletes, especially in sports such as ice hockey.

Non-arthritic hip pain includes a variety of intra-articular diagnoses commonly seen in these athletes that are not directly related to osteoarthritis. These include dysplasia, bony changes, femoroacetabular impingement, labral tears, and more.

A recent clinical practice guideline on this topic was published in JOSPT to help us. In this episode, I talk to the lead author, Keelan Enseki, about the CPG findings.

Show notes

Keelan works at the Rooney Center for Sports Medicine at the University of Pittsburgh Medical Center. He currently serves as director of clinical practice innovation and administrative director of physical therapy residency programs. Keelan is also an adjunct professor at the University of Pittsburgh. In these roles, he divides time between clinical practice, teaching, research/writing, and clinical program design. His clinical interests focus on the nonoperative and postoperative care of individuals with injuries to the hip region. These interests are also represented through collaboration with the Orthopedic and Sports Physiotherapy Academies and the International Society of Hip Arthroscopy (ISHA).

Social tools for COS:
– Instagram: @keelan_enseki

Source link

November 28, 2023
Aclarion announces major commercial milestone with completion of 1,000 Nociscan exams

Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans

Further acceleration in scan volumes is expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons

All commercial Nociscans to date have been completed on Siemens MRI scanners, with additional acceleration in volumes expected as Philips scanners come on board

BROOMFIELD, CO, November 27, 2023 (GLOBE NEWSWIRE) – via NewMediaWire —Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and proprietary enhanced intelligence algorithms to help physicians identify the location of chronic low back pain, today announced it has completed 1,000 commercial Nociscan studies.

“This milestone in itself is significant, but the pace of our commercial adoption is the most exciting aspect of reaching 1,000 commercial scans,” said Brent Ness, CEO of Aclarion. “For context, 36% of these 1,000 studies were conducted in the last twelve months, demonstrating the adoption our strategy has delivered on our journey to a standard of care. As more imaging locations are added and KOLs continue to access Nociscan, we expect to reach the 2,000 scans milestone even faster.”

“This achievement reinforces Aclarion’s clear leadership in the evolving field of augmented intelligence and the renaissance in MR spectroscopy,” said Ryan Bond, Chief Strategy Officer at Aclarion. “Nociscan is the first of its kind, evidence-based SaaS platform that turns volumes of complex data into a clear, streamlined report that efficiently communicates individualized biomarker data to help physicians optimize treatment strategies for patients suffering from chronic low back pain. This is an important commercial milestone for our physician customers, their patients and our team.”

Worldwide, 266 million people suffer from degenerative spinal disorders and lower back pain¹. Conventional imaging and diagnostics provide valuable structural information but struggle to identify the source of the pathogenic pain. Low surgical success rates (41-57%)^2.3 especially for patients suffering from discogenic chronic low back pain (DCLP). Of all disease conditions, low back and neck pain are responsible for the highest healthcare expenditures in the US¹.

Aclarion’s disruptive innovation, Nociscan, emerged over a decade of development. Aclarion’s patent portfolio includes 22 U.S. patents, 17 international patents, 6 pending U.S. patent applications and 7 pending international patent applications, including patents and patent applications exclusively licensed by Regents of the University of California.

Nociscan is currently available from imaging facilities using select models of Siemens 1.5T and 3T magnetic resonance spectroscopy. For more information please contact info@aclarion.com.

About Aclarion, Inc.

Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (MRS), proprietary signal processing techniques, biomarkers and enhanced intelligence algorithms to optimize clinical treatments. The company is entering the chronic low back pain market for the first time with Nociscan, the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies. For more information please visit www.aclarion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the company’s current plans and expectations, as well as its future results of operations and financial condition. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to read the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures in the prospectus and subsequent filings with the Securities and Exchange Commission. . Forward-looking statements in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor contacts:
Kirin M. Smith
PCG Advice, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media contacts:
Jodi Lamberti
SPRIG advice
612.812.7477
jodi@sprigconsulting.com

[1] Ravindra VM, Global Spine Journal (2018) 8(8): 784-794
[2] Wei J, Song Y, et al. Comparison of artificial total disc replacement versus fusion for lumbar disc disease: a meta-analysis of randomized controlled trials. Int Orthop. 2013; 37(7):1315-1325
[3] Ibrahim T, Tieyjeh IM, et al. Surgical versus nonsurgical treatment of chronic low back pain: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113

Source link

November 28, 2023
Researchers develop $1 cancer treatment using engineered bacteria

What if a single dollar dose could cure cancer?

A multi-university team of researchers, supported by federal funding, is developing a highly efficient bacterial therapeutic to target cancer more precisely and make treatment safer via a single $1 dose.

Traditionally, cancer therapies have been limited in their effectiveness in treating patients. Some, such as radiation and chemotherapy, cause harmful side effects, while others tend to result in low patient responsiveness, not to mention the expense required to receive treatment. Findings from the American Cancer Society’s Cancer Action Network show that 73% of cancer survivors and patients worried about how they would pay for their cancer care, and 51% said they had medical debt due to treatment. For example, state-of-the-art cancer therapy can cost up to $1,000,000.

Texas A&M University and the University of Missouri are leading the effort to develop a low-cost, safe and controlled cancer treatment. Researchers received a $20 million grant from the Advanced Research Projects Agency for Health (ARPA-H) to fight cancer. The four-year project is part of the current administration’s Cancer Moonshot initiative, an effort to promote and increase funding for cancer research. It is one of the first projects funded by the newly created agency, which aims to accelerate better health outcomes for all by supporting the development of high-impact solutions to society’s most challenging health problems.

Quickly analyze cells

$12 million of the grant will go to the Texas A&M Engineering Experiment Station/Texas A&M, where co-principal investigators Drs. Arum Han, Jim Song, and Chelsea Hu develop synthetic programmable bacteria for immune-targeted killing in tumor environments (SPIKEs). The idea is to develop bacteria that help T cells kill cancerous tissue, destroy themselves once the cancer is gone, and leave the body safely as human waste.

SPIKEs can specifically target tumor cells. And because it only targets cancerous tissue and not the surrounding healthy cells, patient safety is increased exponentially. It is a great honor to be on this team and tackle a major health problem that affects many people.”

Arum Han, the Texas Instruments professor in the Department of Electrical and Computer Engineering

Han’s laboratory develops high-throughput microfluidic systems that can rapidly process and screen vast bacterial therapeutic libraries, cell by cell, to quickly identify the most promising treatments. These systems are made possible by integrating microfabrication methods and biotechnology to realize a picoliter volume liquid handling system that can accurately analyze single cells with high precision and high speeds, creating devices to rapidly analyze individual cells.

“The biggest challenge is figuring out how to actually develop these advanced microdevices that allow us to run millions and millions of fully automated tests without manual or human intervention,” Han said. “That’s the technical challenge.”

Rescuing anti-tumor immune cells

While Han innovates and designs microdevices, Song -; an immunologist with a background in microbial pathogenesis, T cell biology and T cell-based immunotherapy -; has been working on immunotherapy against bacteria for the past five years. A certain bacteria known as Brucella melitensis can manipulate the human body microenvironment and promote T cell-mediated anti-tumor immunity to treat at least four types of cancer.

“We are working on improvement Brucella melitensis to more efficiently prevent or suppress tumor growth,” said Song, a professor at Texas A&M School of Medicine. “Our current approach involves figuring out how to engineer bacteria to rescue anti-tumor immune cells, thereby increasing their effectiveness in killing tumor cells.

‘That is evident from the data so far BrucellaIts efficiency is dramatically higher than that of other cancer treatments, such as chimeric antigen receptor T-cell therapy and T-cell receptor therapies, with a responsiveness of more than 70%,” said Song.

Safe and controllable therapies

While Song continues to test the bacteria’s efficiency using cancer models, Hu, an assistant professor in the Artie McFerrin Department of Chemical Engineering and a synthetic biologist, is working to ensure the live bacterial therapy is safe and controllable.

“The Brucella The strain we use has been shown to be safe for the hosts because it is an attenuated version, meaning an important gene necessary for bacterial virulence has been deleted,” Hu said. Ultimately, we want to control the speed of the bacteria. growth, where it grows within the tumor environment, and its ability to self-destruct when its mission is complete.”

To control growth rates, the bacteria’s genes will be adjusted to regulate the population and oscillate around a specific set point. Hu also plans to build biosensors into the bacteria, allowing them to distinguish between healthy tissue and tumor tissue, to ensure they grow only within the tumor microenvironment.

The bacterium will be engineered to have a receptor that ensures that once the cancer is gone, the patient can take antibiotics that signal the bacterium to cut itself up and be safely removed from the patient’s body.

“As humans, we are actually covered in bacteria, and many diseases are caused by an imbalance in these bacterial communities,” Hu said. “For example, while some people have incredibly fragile stomachs, others have robust stomachs. The science behind this is that people with a strong immune system and digestive system have a healthy community of bacterial cells in their intestines. There is a lot of potential in living therapies. .”

“It’s really a great opportunity to have an incredible team that has expertise and can push this technology to the front lines,” Hu said. “So that kind of goal is to reach the clinic and provide patients with effective cancer treatment for less than $1 per dose.”

Tackling difficult issues using unconventional approaches

Other collaborators include Dr. Zhilei Chen of the Texas A&M Health Science Center and Dr. Xiaoning Qian of the Department of Electrical and Computer Engineering, along with the principal investigator, Dr. Paul de Figueiredo, of Missouri University.

“The three main advantages of this work are high safety, low cost and specific targeting of cancer tumors,” Han said. “We are very excited to be one of the first teams to receive support from ARPA-H, a brand new agency created and supported by Congress to really tackle tough problems across broad areas of healthcare. We attack difficult problems. problems using unconventional approaches. High risk and high impact is the hallmark of our approach.”

And the future applications of technical bacteria that this research opens up are limitless.

For our next big project, we will work together to develop bacteria against autoimmune diseases such as type 1 diabetes and rheumatoid arthritis,” Song said. Bacteria-based immunotherapy represents a groundbreaking frontier in medicine and offers the potential to revolutionize the treatment of autoimmune diseases. Now that we have harnessed the power of beneficial microbes to modulate the immune system, we are about to change the future of medicine. Our research and expertise hold the promise of transforming the lives of millions of people, offering them new hope and a healthier future.”

Source link

November 28, 2023
Effect of plyometric versus complex training on core, lower extremity and upper extremity strength in male cricketers: a randomized controlled trial BMC Sports sciences, medicine and rehabilitation
Scanlan AT, Berkelmans DM, Vickery WM, Kean CO. An overview of the internal and external physiological demands of batting in cricket. Int J Sports Physiol Perform. 2016;11(8):987–97.

Article PubMed Google Scholar
Ali K, Khan MH. The effects of plyometric training on grass and clay on jumping, sprinting and agility in collegiate cricketers. Int J Biomed Adv Res. 2013;4(12):902–8.

Article Google Scholar
Medicine ACoS. American College of Sports Medicine Position Standard. Progression models in resistance training for healthy adults. Med Sci Sports Exercise. 2009;41(3):687–708.

Article Google Scholar
Grgic J, Schoenfeld BJ, Davies TB, Lazinica B, Krieger JW, Pedisic Z. Effect of resistance training frequency on gains in muscle strength: a systematic review and meta-analysis. Sports Med. 2018;48(5):1207–2020.

Article PubMed Google Scholar
Chu DA, Panariello RA. Jumping plyometrics: Sport-specific plyometrics: Baseball pitching. Nat Strength Cond Assn J. 1989; 11:81–5.

Article Google Scholar
Markovic G. Does plyometric training improve vertical jump height? A meta-analytic review. Br J Sports Med. 2007;41(6):349–55.

Article PubMed PubMed Central Google Scholar
Baechle TR, Earle RW. Basics of strength training and conditioning. 3rd edition. Human kinetics; 2008. p. 417.
Luebbers PE, Potteiger JA, Hulver MW, Thyfault JP, Carper MJ, Lockwood RH. Effects of plyometric training and recovery on vertical jump performance and anaerobic strength. J Strength Cond Res. 2003;17(4):704–9.

PubMed Google Scholar
MacDonald CJ, Lamont HS, Garner JC. A comparison of the effects of six weeks of traditional resistance training, plyometric training, and complex training on strength measurements and anthropometry. J Strength Cond Res. 2012;26(2):422–31.

Article PubMed Google Scholar
Thapa RK, Lum D, Moran J, Ramirez-Campillo R. Effects of complex training on the sprinting, jumping and change of direction ability of football players: a systematic review and meta-analysis. Front Psychol. 2021;11:627869.

Article PubMed PubMed Central Google Scholar
Baker D. Acute effect of alternating heavy and light resistance on power output during complex upper body strength training. J Strength Cond Res. 2003;17(3):493–7.

PubMed Google Scholar
French DN, Kraemer WJ, Cooke CB. Changes in dynamic exercise performance after a series of preconditioning isometric muscle actions. J Strength Cond Res. 2003;17(4):678–85.

PubMed Google Scholar
Fatouros IG, Jamurtas AZ, Leontsini D, Taxildaris K, Aggelousis N, Kostopoulos N, et al. Evaluation of plyometric exercise training, strength training and their combination on vertical jumping performance and leg strength. J Strength Cond Res. 2000;14(4):470–6.

Google Scholar
Ingle L, Sleap M, Tolfrey K. The effect of a complex training and detraining program on selected strength and power variables in early pubertal boys. J Sports science. 2006;24(9):987–97.

Article PubMed Google Scholar
Ebben WP, Jensen RL, Blackard DO. Electromyographic and kinetic analysis of complex training variables. J Strength Cond Res. 2000;14(4):451–6.

Google Scholar
Anant S, Choudhary R, Venugopal R. Effect of core training on anaerobic strength, explosiveness, repetitive strength and endurance of male players. Int Human Res J 2014;2(3):1–8.
Dallas GC, Pappas P, Ntallas CG, Paradisis GP, Exell TA. The effect of four weeks of plyometric training on the reactive strength index and leg stiffness is sport-dependent. J Sports Med Phys Fitness. 2020;60(7):979–84.

Article PubMed Google Scholar
Anant SK, Venugopal R. Effect of eight-week Swiss ball training on the core muscles of male players. Int J Mov Educ Soc Sci. 2015;3(2):53–5.
Army LA, Lambert J. A 20 m maximum multi-stage shuttle run test to predict $$\dot V$$ O2 max. Eur J Appl Physiol. 1982;49(1):1–12.

Article CAS Google Scholar
Lau C, Yu R, Woo J. Effects of a 12-week hatha yoga intervention on cardiorespiratory endurance, muscle strength and endurance and flexibility in Chinese adults in Hong Kong: a controlled clinical trial. Evid-based complement Alternat Med. 2015;2015:12. Article ID 958727. https://doi.org/10.1155/2015/958727.
Rahimi R, Behpur N. The effects of plyometric, weight and plyometric strength training on anaerobic strength and muscular strength Facta universitatis series. Physical Edu Sports. 2005;3(1):81–91.

Google Scholar
Ali K, Verma S, Ahmad I, Singla D, Saleem M, Hussain ME. Comparison of complex versus contrast training on steroid hormones and sports performance in male football players. J Chiropr Med. 2019;18(2):131–8.

Article PubMed PubMed Central Google Scholar
Gabriel DA, Kamen G, Frost G. Neural adaptations to resistance exercise. Sports Med. 2006;36(2):133–49.

Article PubMed Google Scholar
Freitas TT, Martinez-Rodriguez A, Calleja-Gonzalez J, Alcaraz PE. Short-term adaptations after complex training in team sports: a meta-analysis. PLoS One. 2017;12(6): e0180223.

Article PubMed PubMed Central Google Scholar
Hrysomallis C, Kidgell D. Effect of heavy dynamic resistance exercise on acute upper body strength. J Strength Cond Res. 2001;15(4):426–30.

CAS PubMed Google Scholar
Holm L, Reitelseder S, Pedersen TG, Dossing S, Petersen SG, Flyvbjerg A, et al. Changes in muscle size and MHC composition in response to resistance exercise with heavy and light loading intensity. J Appl. Physiol. 2008;105(5):1454–61.

Article CAS PubMed Google Scholar
Evans AK, Durham MP, Hodgkins TD, Sinclair DR, Adams KJ. Acute effects of bench press on power output during a subsequent ballistic bench throw. Med Sci Sports Exercise. 2001;33(5):S325.

Article Google Scholar
Ritchie D, Keogh JWL, Reaburn P, Bartlett JD. The use of one and four minutes of recovery when using the contrast method of resistance training does not negatively impact subsequent jump performance when concurrent training is involved. PeerJ. 2020;13(8):e10031. https://doi.org/10.7717/peerj.10031.PMID:33083124;PMCID:PMC7566756.

Article Google Scholar
McKendry J, Pérez-López A, McLeod M, Luo D, Dent JR, Smeuninx B, et al. Short rest between sets attenuates resistance exercise-induced increases in myofibrillar protein synthesis and intracellular signaling in young men. Exp Physiol. 2016;101(7):866–82.

Article CAS PubMed Google Scholar
Jensen RL. Kinetic responses during landings of plyometric exercises. In Proceedings of the XXVI Congress of the International Society of Biomechanics in Sports (Kwon, YH, Shim, J, Shim, JK, and Shin, IS, editors). 2008; 393–6.
Adams K, O’Shea JP, O’Shea KL, Climstein M. The effect of six weeks of squat, plyometric, and squat-plyometric training on energy production. J Applied Sports Sci Res. 1992;6(1):36–41.

CAS Google Scholar
Herrero J, Izquierdo M, Maffiuletti N, Garcia-Lopez J. Electromyostimulation and plyometric training effects on jumping and sprinting time. Int J Sport Med. 2006;27(07):533–9.

Article CAS PubMed Google Scholar

Scientists have developed a potentially transformative new technique that could help in the discovery and development of new therapies for a number of globally prevalent autoimmune diseases.

Conditions such as lupus, rheumatoid arthritis and inflammatory bowel disease (IBD) – as well as malfunctions in transplanted cells – are all caused by altered cytokine secretion from immune cells in the human body.

To find treatments for such diseases, experts must identify the genetic regulators of secretion so they can explore the most effective ways to inhibit them.

An international team of researchers has developed a new method called Secretion-Enabled Cell Ranking and Enrichment (SECRE), which is detailed in a study published in Nature Biomedical Technology.

They have shown that the method is accurate in sorting hundreds of millions of CRISPR-edited cells based on their secretion patterns, and in identifying the genetic regulators of cytokine secretion in an autoimmune disease. In addition, the method takes into account the detailed profiles of approved treatments and treatments in development to determine whether pre-existing therapies can be repurposed in new ways.

In the study, the researchers describe how they validated their approach against the cells known to play an essential role in the development and severity of IBD, and how they proved that this approach has the potential to find new ways to treat conditions that affect millions of people worldwide. .

The research is the result of a project lasting about four years between scientists from Great Britain, the United States and Canada, leading experts in the field of developing new tools for the diagnosis and treatment of diseases, led by Professor Shana Kelley, chairman of the Chan-Zuckerberg Institute and professor at Northwestern University.

This is an incredibly new approach that has the potential to deliver enormous benefits to patients, doctors and pharmaceutical companies working to develop new treatments. It gives us the opportunity to sort large numbers of cells based on their secretion patterns and identify therapeutic targets that can be applied to help people with conditions for which few therapeutic options currently exist. “Through our existing work we have shown that it has the potential to help identify ways to treat various autoimmune diseases, but my work is now also expanding to types of cancer, including some of the most aggressive types of brain tumors.”

Dr. Mahmoud Labib, a lecturer at the Peninsula Medical School of the University of Plymouth, and the key inventor of the approach

A possible treatment for inflammatory bowel disease?

Inflammatory bowel disease (IBD) is a long-term health condition estimated to affect approximately 7 million people worldwide. It is characterized by chronic inflammation of the digestive tract, which can result in severe abdominal pain and diarrhea, and there is currently no known cure.

As part of their work to validate their approach, the researchers examined the effect of various kinase inhibitors on CD4+ T cells, which are known to produce interferon-gamma, a protein widely implicated in several autoimmune diseases, including IBD. The inhibitors studied included XMU-MP1, a small molecule previously studied as a treatment for heart failure, hair loss and a number of other medical conditions.

In this case, the researchers used XMU-MP1 to treat mice with a form of colitis that has a similar cell secretion profile to that in people with IBD. They found that the mice experienced significantly less weight loss and reduced symptoms of colitis, while their colons appeared almost normal and showed no significant loss of intestinal stem cells.

Based on these findings, the researchers say their results suggest that using XMU-MP1 as a means to inhibit the production of interferon-gamma in the intestines may be an ideal means of controlling IBD. They also say it offers a promising future strategy for the therapeutic molecular targeting of the condition, although extensive clinical trials would be needed before it could be considered as a treatment.

How the SECRE technique works

The Secretion-Enabled Cell Ranking and Enrichment (SECRE) technique captures the secreted cytokine on the surface of the cell. These cytokines are then labeled with magnetic nanoparticles and sorted at high resolution in a microfluidic device fabricated using scaled three-dimensional printing.

The SECRE technique allows rapid and rapid sorting of cells based on their secretion patterns, making it amenable to large-scale functional genetic screening. This approach also links the functional signature of the cell to its phenotype, allowing selective sorting of specific subsets of immune cells based on specific cell surface markers and the secretion-specific factors.

Source:

Magazine reference:

Labib, M., et al. (2023). Identification of druggable regulators of cell secretion via a kinome-wide screen and high-throughput immunomagnetic cell sorting. Nature Biomedical Technology. doi.org/10.1038/s41551-023-01135-w.

Source link

Author: Mokhtar

New Shotel™ medical ankle arthrodesis device significantly improves patient quality of life

DISC Surgery Center in Newport Beach is now enrolling patients in a clinical trial of artificial disc replacement

Non-arthritic hip pain with Keelan Enseki

Show notes

Aclarion announces major commercial milestone with completion of 1,000 Nociscan exams

Researchers develop $1 cancer treatment using engineered bacteria

Quickly analyze cells

Rescuing anti-tumor immune cells

Safe and controllable therapies

Tackling difficult issues using unconventional approaches

Effect of plyometric versus complex training on core, lower extremity and upper extremity strength in male cricketers: a randomized controlled trial BMC Sports sciences, medicine and rehabilitation

Stronger thigh muscles can prevent knee replacement surgery

MCRA Announces Launch of Integrated AI & Imaging Center

SECRE technology paves the way for new therapies for autoimmune diseases

A possible treatment for inflammatory bowel disease?

How the SECRE technique works

Stratasys is collaborating with Siemens Healthineers in a Landmark Research Project to advance medical imaging

Contacts